News
09-29-2014, 11:41 PM
Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal.
More... (http://www.news-medical.net/news/20140930/Pertuzumab-combined-with-trastuzumab-and-chemotherapy-extends-lives-of-HER2-positive-breast-cancer-patients.aspx)
More... (http://www.news-medical.net/news/20140930/Pertuzumab-combined-with-trastuzumab-and-chemotherapy-extends-lives-of-HER2-positive-breast-cancer-patients.aspx)